INTRODUCTION
Heparin and low molecular weight heparin (LMWH) 1 act as anticoagulants by catalyzing antithrombin, a serpin that inactivates thrombin, factor (f.) IXa, and f.Xa (1) . Binding of heparin and LMWH to antithrombin is mediated by a unique pentasaccharide sequence found on one-third of heparin chains and one-fifth of LMWH chains (2) . Pentasaccharide-mediated binding of heparin or LMWH to antithrombin induces a conformational change in the reactive centre loop of antithrombin that facilitates its interaction with f.Xa (3) (4) (5) . Consequently, both agents increase the rate at which antithrombin inhibits f.Xa by two or three orders of magnitude (6, 7) .
Efficient catalysis of thrombin inhibition by antithrombin requires a specific pentasaccharide-containing heparin chain of sufficient length to bridge antithrombin to thrombin, thereby forming a ternary heparin-thrombin-antithrombin complex (8, 9) . Only heparin chains that contain at least 13 saccharide units in addition to the pentasaccharide, or a minimum molecular mass of 5400, are long enough to bridge antithrombin to thrombin (10) . With a mean molecular mass of fondaparinux were similar to those of LMWH or heparin (16) .
F.IXa plays a critical role in the amplification of thrombin generation after clotting is triggered by tissue factor exposure (17, 18) . Several studies have demonstrated that heparin increases the rate of f.IXa inhibition by antithrombin, the predominant inhibitor of f.IXa (19) (20) (21) (22) (23) (24) (25) .
Kinetic analyses suggest that, like the case with thrombin, heparin accomplishes this by serving as a template onto which f.IXa and antithrombin bind. These studies have been corroborated by the identification of the heparin-binding site on f.IXa, which has been localized to a region distinct from the active site of the enzyme (26) . Although kinetic analyses suggest that heparin serves as a template to catalyze f.IXa inhibition by antithrombin, the effect of heparin chain length on this reaction has not been extensively evaluated.
In addition to heparin chain length, divalent cations also influence rates of protease inhibition. Ca +2 enhances the rate of f.Xa inhibition by antithrombin, presumably by inducing the exposure of a heparin-binding site on the protease, thereby allowing formation of a ternary heparinantithrombin-f.Xa complex (27, 28) . This concept is supported by surface plasmon resonance studies demonstrating that the binding of heparin to f.Xa is Ca +2 -dependent (29) . In the same study, it also was determined that heparin binds to f.IXa with a K d of 17.8 nM, but only in the presence of Ca +2
. The Ca
+2
-dependence of the heparin-f.IXa interaction may explain why, depending on the Ca +2 concentration, previous studies reported different rates of f.IXa inactivation by the heparinantithrombin complex (21, 30) .
The purpose of this study was to determine the mechanism of f.IXa inhibition by antithrombin and the role played by Ca
. Preliminary experiments were performed in recalcified plasma to examine the effect of heparin or fondaparinux on antithrombin inhibition of f.IXa generated in situ. To establish the mechanism of heparin-catalysis of f.IXa inhibition by antithrombin, we compared the effects of fondaparinux or heparin on the rates of f.IXa inhibition in a buffer system in the absence and presence of Ca
. The influence of these glycosaminoglycans on the rates of f.Xa and thrombin inhibition by antithrombin also were determined for comparative purposes.
by guest on November 19, 2017 http://www.jbc.org/ Downloaded from 7 Mississauga, ON) were mixed and incubated for 10 min at 37 /C. Subsequently, one-tenth volume of 20 mM Tris-HCl, pH 7.4, 150 mM NaCl (TS) containing 0.01% polyethylene glycol (TSP), 6
µg/ml fondaparinux, or 6 µg/ml heparin was added to one of three tubes together with CaCl 2 to a final concentration of 16 mM. Immediately after CaCl 2 addition, and at timepoints thereafter, triplicate aliquots of 4 -6 µl were removed into separate tubes containing 10 µl SDS gel sample buffer. Samples were placed in a boiling water bath for 3 min prior to electrophoresis on three 4-15% polyacrylamide gels (Criterion, BioRad, Mississauga ON). Standards containing zymogen, enzyme, and enzyme-antithrombin complex were included in each gel. After separating the proteins, the gels were blotted onto nitrocellulose membranes using a Transblot device, according to the manufacturer's instructions (BioRad). Membranes were blocked by incubation in 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.02% Tween-80 (TBS-Tw) containing 5% skim milk powder for 45 min at 23/C. After aspiration of the buffer, the membrane was incubated for 90 min with the antibody diluted in TBS containing 0.05% Tween-80. The membrane was then washed four times, for 5 min each, with TBS-Tw and then incubated with a detecting antibody. In all cases, chemiluminescence (ECL, Amersham-Pharmacia Biotech) was used to detect horseradish peroxidase (HRP)-linked second antibodies. Membranes were exposed to radiographic film for varying lengths of time and autoradiographs were scanned by densitometry (ImageMaster; Amersham-Pharmacia Biotech) and band densities were quantified using the instrument software. Membranes were stripped for reuse by washing for 30 min at 50/C in 62 mM Tris-HCl pH 6.7, 2% SDS, 70 mM mercaptoethanol.
Various antibodies were used for blotting; for f.IX, the first antibody was a mouse monoclonal antibody against human f.IX (Research Diagnostics Inc., Flanders, NJ), whereas the detecting antibody was a HRP-conjugated goat anti-mouse antibody (BioRad). For f.X, the first antibody was a mouse monoclonal antibody against the light chain of human f.X (Sigma) while the second antibody was a HRP-conjugated goat anti-mouse antibody (BioRad). For f.II, the first antibody was a sheep polyclonal antibody against human thrombin (Research Diagnostics Inc.) and the second antibody was a HRP-conjugated donkey anti-sheep antibody (Sigma).
Effect of glycosaminoglycans on the rates of f.IXa, f.Xa, and f.IIa inhibition by antithrombin
Rates of f.IXa, f.Xa and thrombin inhibition by antithrombin were measured in a discontinuous assay under pseudo-first-order rate conditions at 23/C in TS buffer containing 0.5%
Prionex (27, 32) . Heparin and fondaparinux were tested at concentrations ranging from 0-12000
:g/ml. Enzyme concentrations ranged from 1 nM to 500 nM and antithrombin concentrations from The apparent second order inhibition rate constant (k 2 ) was determined by dividing k 1 by the antithrombin concentration.
Binding Experiments
The affinity of fluorescein-HS-LMWH for f.IXa was measured as previously described and competition experiments were then performed to determine the affinities of heparin and fondaparinux for f.IXa (31) . Briefly, the affinity of fluorescein-HS-LMWH for f.IXa was determined by monitoring fluorescence of a titration of fluorescein-HS-LMWH with f.IXa. The affinity of unlabeled heparin or fondaparinux was then measured in separate experiments where fluorescein-HS-LMWH was displaced from a fixed concentration of f.IXa by increasing concentrations of competing glycosaminoglycan.
RESULTS

Influence of fondaparinux and heparin on inhibition of thrombin, f.IXa, and f.Xa in activated plasma
Plasma experiments were performed to verify f.IXa inhibition by antithrombin and to determine the extent to which the reaction was promoted by fondaparinux or heparin. For comparative purposes, the inhibition of thrombin and f.Xa also was monitored. Defibrinogenated platelet-poor plasma was recalcified and activated at 23/C with Thrombosil, an agent that uses silica to activate the intrinsic pathway of coagulation, in the absence or presence of 0.6 µg/ml fondaparinux (0.33 µM) or heparin (0.04 µM). Aliquots were removed at various times and the extent of enzyme-inhibitor complex formation was assessed by SDS-PAGE followed by immunoblot analysis using antibodies that recognize the zymogen-, activated-, and antithrombin inhibited-forms of factors IX, X, or II (Fig. 1 ). Mobility and immunoreactivity of these forms were verified with markers prepared from purified zymogens, enzymes, and enzyme-antithrombin complexes.
by antithrombin.
In the absence of glycosaminoglycan, f.X was activated more rapidly than f.IX, with about 80% f.X activation by 5 min. Free f.Xa accumulated to a lesser extent than f.IXa. However, much of f.Xa (70%) was rapidly inhibited by antithrombin in the absence of glycosaminoglycan.
Consequently, f.Xa-antithrombin complexes formed earlier than f.IXa-antithrombin complexes and there was greater inhibition of f.Xa. In the presence of heparin, activation of f.X was attenuated, with only about 50% activation after 15 min. It is likely that retarded f.X activation reflects the inhibitory effect of heparin on upstream steps in the coagulation system, including inhibition of f.IXa. In comparison to heparin, fondaparinux had less effect on the time course of f.X activation.
Like heparin however, fondaparinux reduced accumulation of free f.Xa and promoted formation of f.Xa-antithrombin complexes.
Prothrombin was activated more rapidly than f.IX or f.X in the absence of glycosaminoglycan, reaching full activation by 2 min. Levels of free thrombin rapidly reached 30%, and declined to about 5% after 15 min. Free f.Xa also showed a rapid increase with subsequent decline, whereas f.IXa demonstrated a gradual increase in concentration. Heparin delayed activation of prothrombin, as expected. Heparin was more effective at promoting thrombin inhibition by antithrombin than it was at enhancing f.Xa inhibition, a finding that is consistent with inhibition rate constants. Fondaparinux had little effect on prothrombin activation or thrombin inhibition in these experiments.
Heparin-catalyzed rates of f.IXa inhibition
To investigate the mechanism of heparin catalysis of f.IXa inhibition by antithrombin, rate constants of inhibition were determined under pseudo-first-order conditions in the absence or presence of fondaparinux or heparin. Use of a f.IXa fluorogenic substrate permitted sensitive determination of residual f.IXa activity in the inhibition assays (33) . In the presence of 2 mM CaCl 2 , the plot of the second order rate constants of f.IXa inhibition by antithrombin versus heparin concentration in 2 mM CaCl 2 is bell-shaped ( Fig. 2A) , characteristic of a template mechanism of catalysis. The uncatalyzed rate of f.IXa inhibition by antithrombin, 1.34 x 10 4 M -1 min -1 , was increased up to 1210-fold by heparin to a maximum rate of inhibition of 1.62 x 10 7 M -1 min -1 (Table   I ). Heparin caused a concentration-dependent increase in f.IXa inhibition in the presence of 2 mM :g/ml (0.33 µM). To compare the effects of fondaparinux and heparin on the relative increases in the rate of f.IXa inhibition by antithrombin, the maximum second-order rate constants of fondaparinux-and heparin-catalyzed inhibition were divided by the uncatalyzed rates of inhibition.
Fondaparinux produces a maximal 107-fold increase in the rate of inhibition of f.IXa by antithrombin compared with the rate measured in the absence of glycosaminoglycan (Fig. 3 ). With heparin, the rate is increased 1210-fold. Thus, heparin increases the rate of f.IXa inhibition by antithrombin 11-fold more than fondaparinux.
In contrast to the current results, a recent study failed to show a catalytic influence of fondaparinux on antithrombin inhibition of f.IXa (34) . Methodological differences may account for these disparate results. We used a kinetic approach in the current study, whereas a single time point, measured in the absence of Ca
+2
, was used to quantify inhibition in the work of Herault and colleagues. In addition, we directly quantified residual f.IXa activity by chromogenic assay, whereas an indirect tenase system was used in the previous publication. Another study, using methods similar to ours, demonstrates pentasaccharide-mediated stimulation comparable to that reported here (26) .
Rates of f.Xa and thrombin inhibition by antithrombin
Because the mechanisms by which heparin catalyzes the inhibition of f.Xa and thrombin by antithrombin are distinct, inhibition studies of these two enzymes were performed for comparison purposes. In the presence of 2 mM CaCl 2 , heparin produced a 1900-fold increase in the rate of f.Xa inhibition by antithrombin (from 1.83 x 10 5 M -1 min -1 to 3.47 x 10 8 M -1 min -1 ) ( Fig. 2 ; Table I ). The k 2 value continued to increase as a function of heparin concentration until a plateau was reached at a heparin concentration of approximately 6 :g/ml (0.4 µM). Heparin concentrations over 200 :g/ml (13 :M) caused dose-dependent decreases in the rate of f.IXa inhibition by antithrombin ( Fig. 2A) .
When the rate of f.Xa inhibition by antithrombin is plotted versus fondaparinux concentration, there is a concentration-dependent increase until a plateau of 2.85 x 10 7 M -1 min -1 is reached with a fondaparinux concentration of 0.6 :g/ml (0.33 µM) (Fig. 2B) . The effect of fondaparinux on the rate of f.Xa inhibition by antithrombin was similar to its effect on the rate of f.IXa inhibition (Fig. 3) , with maximum stimulation of 156-and 107-fold, respectively. Like f.IXa, the rate of f.Xa inhibition by antithrombin is 11-to 12-fold higher with heparin than with fondaparinux ( Fig. 3) . These values are in agreement with earlier reports demonstrating that rates of f.Xa inhibition with heparin are higher than those with pentasaccharide (8, 27) .
The plots of the second-order rate constants of f.IXa and f.Xa inhibition by antithrombin versus fondaparinux concentration both reach a plateau. However, the approximate 10-fold lower basal rate of inhibition of f.IXa versus f.Xa in the absence of a glycosaminoglycan is maintained in the presence of fondaparinux. The results presented here suggest that the mechanism of heparininduced catalysis of f.IXa inhibition by antithrombin closely resembles that for f.Xa. In both cases, pentasaccharide-induced conformational changes in antithrombin enhance the serpin's reactivity with the target protease. However, Ca
+2
-dependent bridging by longer heparin chains produces a further enhancement in the rate of the inhibition reaction.
Heparin showed a typical template effect on the rates of thrombin inhibition by antithrombin, yielding a bell-shaped curve ( Fig. 2A) , as observed for f.IXa and f.Xa. The basal rate was 2.89 x 10 5 M -1 min -1 and increased to a maximum of 7.14 x 10 8 M -1 min -1 in the presence of heparin. The 2470-fold increase in the rate of thrombin inhibition produced by heparin was greater than the enhancement it produced in the rates of f.IXa or f.Xa inhibition (Fig. 3) . The similar ascending portions of the f.IXa, f.Xa, and thrombin inhibition curves reflect the affinity of heparin for antithrombin (35) . The peak and descending arms of the f.IXa and f.Xa plots occur at higher heparin concentrations than the peak of the thrombin inhibition plot, suggesting that the affinity of heparin for f.IXa and f.Xa is lower than that for thrombin. 
Heparin binding to f.IXa
The template mechanism suggested by the heparin dose-response of f.IXa inhibition provides evidence for a heparin-f.IXa interaction. This concept is supported by experiments demonstrating that f.IXa binds to heparin-Sepharose (26, 37) . Factor Xa and thrombin also bind to heparinSepharose; however, f.Xa only binds effectively in the presence of Ca +2 (27) . The Ca
+2
-dependence of the heparin-f.Xa interaction is demonstrated by the fact that the heparin-catalyzed rate of f.Xa inhibition by antithrombin is increased 13-fold in the presence of Ca +2 compared with that measured in its absence (27) . Based on a previous study demonstrating that heparin-catalyzed inhibition of f.IXa by antithrombin was stimulated 6-fold by 5 mM Ca +2 (21), we hypothesized that Ca , a similar mechanism of heparin binding is suggested for both proteases. This is consistent with the demonstration of similar heparin affinities of Gla-domainless forms of factors IXa and Xa (26) . evoked up to a 9-fold increase in the rate of heparin-catalyzed inhibition over a range of heparin concentrations (Fig. 6A ). Both f.IXa and f.Xa displayed bell-shaped dose response profiles in the presence of EDTA, suggesting that heparin plays a template role in the absence of Ca
Effect of Ca
+2
. As expected, Ca +2 had no effect on the heparin-catalyzed rates of thrombin inhibition (not shown).
Ca +2 also increased the extent to which fondaparinux enhanced f.IXa inhibition by antithrombin (Fig. 5B) . The maximum stimulation of the rate of fondaparinux-catalyzed f.IXa inhibition by antithrombin was about 110-fold in the absence or presence of 2 mM CaCl 2 . Over the range of fondaparinux concentrations tested, Ca +2 enhanced the rate of f.IXa inhibition from 6-to 20-fold. In contrast, Ca +2 had no effect on the fondaparinux dose-response with f.Xa (Fig. 6B) .
DISCUSSION
When the intrinsic pathway of coagulation was activated in plasma, antithrombin was the predominant inhibitor of generated f.IXa. Inhibition by antithrombin is consistent with results of earlier studies where 125 I-f.IXa was added to plasma (24) . To examine the role of glycosaminoglycans, the intrinsic pathway of coagulation also was activated in the presence of fondaparinux or heparin. Fondaparinux and heparin significantly promoted f.IXa inhibition by antithrombin to a similar extent. As expected, fondaparinux also enhanced f.Xa inhibition by antithrombin, but had no effect on thrombin inhibition. These studies verify that f.IXa inhibition by antithrombin is promoted by fondaparinux under conditions where f.IX is activated in plasma.
Because fondaparinux was as effective as heparin in this assay, detailed kinetic studies were performed in purified systems to quantify the relative effects of these two glycosaminoglycans on the rates of f.IXa inhibition by antithrombin. To permit mechanistic comparisons, their effects on the rates of f.Xa and thrombin inhibition by antithrombin were assayed in parallel experiments.
Because vulnerability to inhibition in the presence of the heparin pentasaccharide distinguishes f.Xa from thrombin and the template from conformational change models, quantification of fondaparinux contribution to the rate of f.IXa inhibition by antithrombin was determined. In the presence of Ca
+2
, fondaparinux produced a 107-fold increase in the rate of f.IXa inhibition by antithrombin. With f.Xa, fondaparinux produced a 156-fold increase in the rate of inhibition, whereas it had only a 2-fold effect on the rate of thrombin inhibition. By comparison, heparin increased the rates of f.IXa and f.Xa inhibition by antithrombin 1210-fold and 1900-fold,
respectively. These results demonstrate a similarity in the mechanism of glycosaminoglycan stimulation of inhibition of f.IXa and f.Xa by antithrombin. Thus, heparin enhances the rate of f.IXa inhibition by antithrombin by about three orders of magnitude, whereas fondaparinux increases this rate by two orders of magnitude. These observations suggest that the 10-fold superiority of heparin over fondaparinux reflects the capacity of the longer heparin chains to bridge f.IXa to antithrombin.
Confirmation of this template mechanism comes from the observation that the heparin dose response for the inhibition of f.IXa by antithrombin is biphasic, with a bell-shaped profile similar to that for thrombin and f.Xa. F.Xa was only recently recognized to utilize this mechanism when it was determined that the enzyme binds heparin in the presence of Ca +2 (27) . It was proposed that the Gla-domain of f.Xa obscures or binds to the heparin-binding site on f.Xa in the absence of Ca +2 .
In the presence of Ca +2 , the heparin-binding site is exposed. Because f.IXa and f.Xa are homologous proteins with similar domain structures (38, 39) , the potential role of Ca +2 in mediating interaction of heparin with f.IXa was investigated. antithrombin that is complementary to an exosite that resides near the active site of f.Xa (46) . This promotes association of inhibitor and enzyme through a mechanism distinct from that provided by a heparin template. By extension, a similar exosite may exist on f.IXa that permits reactivity with pentasaccharide-activated antithrombin.
Effect of Ca
Physiological considerations and implications
The results of experiments in plasma demonstrate that f.IXa displays a greater resistance to inhibition than f.Xa, even in the presence of heparin or fondaparinux. This could result from the lower rate constant for inhibition or from protection of f.IXa from antithrombin by assembly into the intrinsic tenase complex. The latter phenomenon has been observed with f.Xa within the prothrombinase complex and has been attributed to the competitive effect of the substrate prothrombin on interaction of f.Xa with antithrombin (47, 48) . Thus, f.IXa within its activation complex may be better protected than f.Xa in prothrombinase. Agents that disrupt these activation complexes may then permit greater access of antithrombin to the protease components. HS-LMWH fits this description as it disrupts both prothrombinase and intrinsic tenase complexes, likely by binding to the heparin-binding sites on f.Xa and f.IXa, respectively (31) . Therefore, the heparinbinding site on f.IXa plays an important physiological role that may be exploited for therapeutic purposes.
f.IXa is a second physiological target of fondaparinux
Fondaparinux has been considered to specifically target f.Xa in an antithrombin-dependent fashion. Because early studies failed to identify an effect of fondaparinux on the inhibition of f.IXa, the anticoagulant mechanism of fondaparinux has only been considered from the perspective of f.Xa and thrombin. However, the striking effect of fondaparinux on the rate of inhibition of f.IXa suggests that anti-f.IXa action may contribute to the effectiveness of this drug. Although antithrombin inhibits f.IXa at lower rates than f.Xa, the position of f.IXa upstream of f.Xa in the coagulation cascade provides an opportunity for an intensified downstream effect.
Advancing our understanding of the anticoagulant mechanism of fondaparinux may help (Fig. 2) and are plotted as fold increase over the uncatalyzed rate of inhibition. 
